{"paper_id":"ec3475b2-ef36-41ab-96bb-7b811c051c2a","body_text":"Prolonged Pregnancy Following Long-Term Celecoxib Use in a Case of Uterine Adenomyosis: A Case Report\nFunding: The authors received no specific funding for this work.\nABSTRACT\nNonsteroidal anti-inflammatory drugs (NSAIDs) are generally avoided in late pregnancy due to fetal risks, such as premature ductus arteriosus closure. However, celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, may help manage pain and uterine contractions with fewer adverse effects. Here, we report a case of a 37-year-old primiparous woman with uterine adenomyosis who was treated with celecoxib and ritodrine hydrochloride for severe pain and threatened preterm labor in the second trimester. This combination effectively reduced symptoms, allowing prolongation of pregnancy. However, labor commenced shortly after discontinuation of celecoxib at 28 weeks of gestation, requiring an emergency cesarean section. The neonate had no significant complications, and the patient's pain resolved postpartum. This case demonstrates that celecoxib can be a viable option for managing pain and contractions in pregnancy complicated by adenomyosis; however, further studies are needed to assess its long-term safety.\nConflicts of Interest\nDr. Takeda Jun is an Editorial Board member of the JOGR Journal and a co-author of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication.\nData Availability Statement\nData sharing not applicable to this article as no datasets were generated or analyzed during the current study.","source_license":"public-domain-us","license_restricted":false}